Swedish Orphan Biovitrum AB (publ) (SOBIS.XC)
| Previous close | 264.90 |
| Open | 264.90 |
| Bid | 264.80 x 0 |
| Ask | 282.40 x 0 |
| Day's range | 264.90 - 264.90 |
| 52-week range | 185.25 - 290.60 |
| Volume | |
| Avg. volume | 14 |
| Market cap | 96.998B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 41.85 |
| EPS (TTM) | 6.33 |
| Earnings date | 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
PR NewswireSobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
PR NewswireNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
